drugset / Trial / NCT05296603
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to explore the efficacy and biomarker explanation of IBI-322 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line PD-(L)1 inhibitors.
Timeline
- Start
- 2021-12-03
- Primary completion
- 2024-10-30
- Completion
- 2025-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI322 | Monoclonal antibody | 10 mg | — |
| Subject | Lenvatinib | Small molecule | — | — |